Skip to main content
. Author manuscript; available in PMC: 2015 Oct 10.
Published in final edited form as: J Control Release. 2014 Jul 10;191:15–23. doi: 10.1016/j.jconrel.2014.07.003

Figure 6. Pharmacokinetics of L4F-A192 nanoparticles and free L4F do not differ significantly.

Figure 6

Rats were injected via the tail vein with a bolus of either fluorescently labeled L4F-A192 or the free L4F peptide. Plasma concentrations were quantified over a three-hour window and data were fit by a single exponential decay. Both treatments revealed an approximately 1 hour half life and no significant difference was detected between in clearance; however, the volume of distribution for the L4F-A192 vesicles was approximately twice that observed for the free L4F peptide (Table 2).